Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 697 - 704 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC3887 | Purvalanol B |
|
Cyclin-dependent kinase inhibitor. IC50 values are 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively. Selective over a range of other protein kinases (IC50 > 10,000 nM). Shown to have antiproliferative properties, mediated by p42/p44 MAPK.
|
|
| BCC3890 | Adaphostin |
|
p210<sup>bcr/abl</sup> tyrosine kinase inhibitor (IC<sub>50</sub> = 14 <span class='symbol'>μ</span>M). Induces apoptosis in T-lymphoblastic human leukemia cell lines (IC<sub>50</sub> values range from 16.8 to 216.3 nM) <em>in vitro</em>. Displays selectivity for chronic myelogenous leukemia (CML) myeloid progenitors <em> in vitro</em>.
|
|
| BCC3891 | GNF 2 |
|
Allosteric inhibitor of Bcr-Abl tyrosine kinase activity (IC50 = 267 nM); inhibits proliferation and induces apoptosis in Bcr-Abl-expressing cells. Selective for Bcr-Abl over a panel of serine, threonine and tyrosine kinases. Non-ATP-competitive.
|
|
| BCC3892 | GNF 5 |
|
Selective, non-ATP competitive allosteric inhibitor of Bcr-Abl (IC<sub>50</sub> = 220 nM for wild-type Abl). Binds the myristate-binding site of Abl. Acts in combination with nilotinib to inhibit T315I Bcr-Abl <em>in vitro</em> and <em>in vivo</em>. Analog of GNF 2.
|
|
| BCC3893 | 1-Naphthyl PP1 |
|
Selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl. (IC<sub>50</sub> values are 1.0, 0.6, 0.6, 18 and 22 <span class='symbol'>μ</span>M for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively). Preferentially inhibits mutant over wild-type kinases (IC<sub>50</sub> values are 1.5 vs 1000 nM for I338G v-src and v-src respectively).
|
|
| BCC3894 | PD 180970 |
|
ATP-competitive inhibitor of p210bcr/abl tyrosine kinase; selectively induces apoptosis in chronic myeloid leukemia (CML) K562 cells. Inhibits in vivo tyrosine phosphorylation of Gab2, CrkL and p210bcr/abl (IC50 values are 80, 80 and 170 nM respectively). Potently inhibits p210bcr/abl autophosphorylation in vitro (IC50 = 5 nM). Also potently inhibits c-Src and KIT (IC50 values are 0.8 and 50 nM, respectively).
|
|
| BCC3895 | PPY A |
|
Potent inhibitor of T315l mutant and wild-type Abl kinases (IC50 values are 9 and 20 nM, respectively). Inhibits growth of cells transformed with either the Bcr-Abl T315l mutant or wild-type Bcr-Abl gene.
|
|
| BCC3896 | CH 223191 |
|
Potent aryl hydrocarbon receptor (AhR) antagonist (IC<sub>50</sub> = 30 nM). Exhibits no AhR agonist-like activity (at concentrations up to 100 <span class='symbol'>μ</span>M). Inhibits 2,3,7,8-Tetrachlorodibenzo-<em>p</em>-dioxin (TCDD)-induced AhR-dependent transcription <em>in vitro</em> and reduces TCDD-induced toxicity <em>in vivo</em>. Attenuates Th17 differentiation of naive CD4 T cells and promotes expansion of hematopoietic stem cells <em>in vitro</em>.
|
|